Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld Sells 75 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $147.35, for a total value of $11,051.25. Following the transaction, the executive vice president directly owned 21,084 shares of the company’s stock, valued at $3,106,727.40. This represents a 0.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Monday, April 27th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $151.94, for a total value of $11,243.56.
• On Thursday, February 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $181.84, for a total value of $13,638.00.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $147.38 on Thursday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $40.61 billion, a P/E ratio of 37.31, a P/E/G ratio of 10.46 and a beta of 0.22. The business has a fifty day simple moving average of $152.11 and a two-hundred day simple moving average of $177.44. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is currently 106.33%.

Institutional Investors Weigh In On Becton, Dickinson and Company

Large investors have recently bought and sold shares of the business. Activest Wealth Management increased its holdings in Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 97 shares in the last quarter. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company in the 3rd quarter worth about $25,000. Steph & Co. increased its holdings in Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares in the last quarter. SHP Wealth Management bought a new stake in Becton, Dickinson and Company in the 4th quarter worth about $26,000. Finally, Meeder Asset Management Inc. increased its holdings in Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BDX has been the subject of several recent analyst reports. Piper Sandler lowered their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research report on Tuesday, April 14th. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a research report on Friday, April 10th. They issued a “neutral” rating and a $167.00 price target for the company. Argus lowered their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. Finally, Wells Fargo & Company lifted their price target on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average price target of $184.86.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.